07:00 , Apr 3, 2006 |  BC Week In Review  |  Clinical News

Bispectral index technology: Phase IV started

Aspect began the double-blind, dose-escalation, U.S. Phase IV BRITE trial in 375 patients with the most recent episodes lasting >2 weeks to predict response to escitalopram, bupropion and a combined therapy using selected electroencephalogram (EEG)...
08:00 , Dec 23, 2002 |  BC Week In Review  |  Company News

Protalex management update

Protalex Inc. (PRTX), Albuquerque, N.M.   Business: Autoimmune/Inflammation   Hired: Steven Kane as CEO and president, formerly VP of North American sales & field operations at Aspect Medical  ...